HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Stephen M Hahn Selected Research

Prostatic Neoplasms (Prostate Cancer)

4/2015A case-matched study of toxicity outcomes after proton therapy and intensity-modulated radiation therapy for prostate cancer.
9/2013What's in a Label? Radioimmunotherapy for metastatic prostate cancer.
5/2013Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer.
5/2012Prospective preference assessment of patients' willingness to participate in a randomized controlled trial of intensity-modulated radiotherapy versus proton therapy for localized prostate cancer.
8/2008Motexafin lutetium-photodynamic therapy of prostate cancer: short- and long-term effects on prostate-specific antigen.
9/2006Real-time in situ monitoring of human prostate photodynamic therapy with diffuse light.
1/2006Updated results of a phase I trial of motexafin lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer.
6/2005Determination of the distribution of light, optical properties, drug concentration, and tissue oxygenation in-vivo in human prostate during motexafin lutetium-mediated photodynamic therapy.
9/2004Interstitial photodynamic therapy for prostate cancer: a developing modality.
2/2002Rates of unconventional medical therapy use in patients with prostate cancer: standard history versus directed questions.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Stephen M Hahn Research Topics

Disease

71Neoplasms (Cancer)
01/2020 - 02/2002
27Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
10/2019 - 05/2002
11Hypoxia (Hypoxemia)
09/2012 - 03/2004
10Prostatic Neoplasms (Prostate Cancer)
04/2015 - 02/2002
8Sarcoma (Soft Tissue Sarcoma)
10/2020 - 03/2004
8Lung Neoplasms (Lung Cancer)
01/2018 - 05/2002
7Neoplasm Metastasis (Metastasis)
10/2020 - 03/2006
7Brain Neoplasms (Brain Tumor)
09/2015 - 03/2004
7Glioblastoma (Glioblastoma Multiforme)
04/2014 - 05/2007
6Malignant Mesothelioma
03/2017 - 03/2003
6Mesothelioma
05/2012 - 03/2003
5Carcinoma (Carcinomatosis)
06/2014 - 05/2002
4Circulating Neoplastic Cells
11/2018 - 06/2014
4Melanoma (Melanoma, Malignant)
11/2018 - 01/2015
4Head and Neck Neoplasms (Head and Neck Cancer)
05/2015 - 05/2002
3Pleural Effusion (Pleural Effusions)
03/2010 - 01/2006
3Pancreatic Neoplasms (Pancreatic Cancer)
09/2005 - 08/2004
3Necrosis
09/2004 - 04/2003
2Radiation Pneumonitis
01/2019 - 09/2010
2Body Weight (Weight, Body)
03/2010 - 01/2006
2Noninfiltrating Intraductal Carcinoma (DCIS)
02/2010 - 09/2009
2Peritoneal Neoplasms
04/2006 - 01/2005
2Ovarian Neoplasms (Ovarian Cancer)
10/2005 - 03/2004
2Capillary Leak Syndrome
07/2003 - 06/2003
1Spontaneous Fractures (Pathological Fracture)
01/2019
1Adenocarcinoma
01/2019
1Pain (Aches)
01/2019
1Anemia
01/2018
1Small Cell Lung Carcinoma (Small Cell Lung Cancer)
01/2018
1Mediastinal Diseases
01/2018
1Hydronephrosis
01/2017
1Lymphoma (Lymphomas)
09/2016
1Chordoma
05/2016

Drug/Important Bio-Agent (IBA)

231-phenyl-3,3-dimethyltriazene (PDT)IBA
01/2020 - 01/2002
8Oxygen (Dioxygen)IBA
07/2011 - 03/2004
8Dihematoporphyrin Ether (Porfimer Sodium)FDA Link
01/2009 - 04/2003
7Nelfinavir (Viracept)FDA Link
10/2019 - 09/2006
7Protons (Proton)IBA
01/2017 - 05/2013
7Photosensitizing Agents (Photosensitizers)IBA
04/2006 - 03/2002
5Telomerase (Telomerase Reverse Transcriptase)IBA
01/2020 - 04/2014
5azomycinIBA
11/2010 - 12/2004
5motexafin lutetium (Lutrin)IBA
08/2008 - 01/2002
5Farnesyltranstransferase (Farnesyltransferase)IBA
09/2005 - 05/2002
4Hemoglobins (Hemoglobin)IBA
01/2018 - 05/2002
4Biomarkers (Surrogate Marker)IBA
01/2018 - 08/2013
3ErbB Receptors (EGF Receptor)IBA
01/2020 - 08/2009
3HIV Protease InhibitorsIBA
10/2019 - 09/2006
3Protease Inhibitors (Protease Inhibitor)IBA
01/2014 - 05/2007
3L 778,123IBA
11/2004 - 05/2002
2CytokinesIBA
01/2019 - 07/2003
2AntibodiesIBA
01/2017 - 06/2010
2Complement System Proteins (Complement)IBA
11/2016 - 01/2015
2AntigensIBA
05/2016 - 09/2013
2Temozolomide (Temodar)FDA LinkGeneric
01/2014 - 05/2007
2GoldIBA
12/2013 - 08/2013
2Proteins (Proteins, Gene)FDA Link
08/2011 - 09/2005
2Biological FactorsIBA
02/2010 - 09/2009
2Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
08/2009 - 09/2006
2Prostate-Specific Antigen (Semenogelase)IBA
08/2008 - 02/2002
2acetamideIBA
12/2004 - 07/2004
2tempolIBA
10/2004 - 01/2003
2nitroxylIBA
10/2004 - 01/2003
1Reactive Oxygen Species (Oxygen Radicals)IBA
01/2020
1Morphine (MS Contin)FDA LinkGeneric
01/2019
1Opioid Analgesics (Opioids)IBA
01/2019
1Analgesics (Analgesic Drugs)IBA
01/2019
1pembrolizumabIBA
11/2018
1IronIBA
01/2018
1HepcidinsIBA
01/2018
1insulin receptor-related receptor (IRR)IBA
01/2018
1Pemetrexed (MTA)FDA Link
03/2017
1P 536IBA
01/2017
1Immune Checkpoint InhibitorsIBA
11/2016
1Carcinoembryonic AntigenIBA
05/2016
1Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA
05/2016
1CalreticulinIBA
05/2016
1Mucin-1 (CA 15-3 Antigen)IBA
05/2016
1Phosphates (Orthophosphate)IBA
03/2016
1VaccinesIBA
03/2016
1GuanineIBA
03/2016
1CTLA-4 AntigenIBA
03/2016

Therapy/Procedure

48Radiotherapy
01/2019 - 05/2002
27Photochemotherapy (Photodynamic Therapy)
01/2020 - 01/2002
21Therapeutics
01/2019 - 02/2002
13Drug Therapy (Chemotherapy)
10/2020 - 03/2006
10Proton Therapy
01/2019 - 05/2012
6Immunotherapy
01/2019 - 11/2015
6Pneumonectomy (Lung Volume Reduction)
05/2012 - 03/2003
5Chemoradiotherapy
10/2019 - 07/2011
5Combined Modality Therapy
01/2018 - 03/2003
4Re-Irradiation
01/2019 - 05/2015
3Adjuvant Radiotherapy
04/2012 - 11/2009
2Precision Medicine
12/2013 - 08/2013
2Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated)
05/2013 - 05/2012
2Aftercare (After-Treatment)
09/2006 - 01/2006
2Electrodes (Electrode)
12/2004 - 03/2004
1Salvage Therapy
01/2018
1Stents
01/2017
1Heavy Ion Radiotherapy
01/2017
1Particle Accelerators
07/2016